Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial
Launched by UNIVERSITY OF NEW MEXICO · Oct 5, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The HOPE Trial is a research study aimed at helping people who struggle with opioid use disorder (OUD) and also have chronic pain. The goal is to find out if a specific treatment that combines two approaches—Acceptance and Commitment Therapy (ACT) and Mindfulness-Based Relapse Prevention (MBRP)—can better help these individuals manage their pain while also preventing a return to opioid misuse. About 160 participants will be included in this study, all of whom are currently receiving treatment for OUD and have been stabilized on a medication called buprenorphine for at least a month.
To be eligible for the trial, participants need to be at least 18 years old, have chronic pain lasting over six months, and be willing to follow the study rules. They should also be patients at one of the participating clinics. During the study, participants will be randomly assigned to either receive enhanced usual care or the new combined treatment. This trial is currently recruiting, and everyone involved can expect to be part of a supportive environment aimed at improving their health and well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Stabilized on a dose of buprenorphine for a period of at least 1 month. Buprenorphine stabilization will be defined as a consistent dose for at least 30 consecutive days.
- • 2. Willing to comply with all study procedures and be available for the duration of the study.
- • 3. Aged 18 years or older.
- • 4. Enrolled as a patient in one of the participating clinics.
- • 5. Presence of chronic pain for \> 6 months in duration.
- Exclusion Criteria:
- • 1. Current or past diagnosis of schizophrenia, delusional disorder, psychotic or dissociative disorders.
- • 2. Unable to read English.
- • 3. Have a substance use disorder requiring a higher level of care than outpatient treatment (e.g., severe alcohol use disorder requiring inpatient detoxification).
About University Of New Mexico
The University of New Mexico (UNM) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a robust commitment to improving patient outcomes, UNM leverages its interdisciplinary expertise and state-of-the-art facilities to conduct cutting-edge clinical research across various fields. The university fosters collaboration among researchers, clinicians, and community partners, ensuring that its trials are not only scientifically rigorous but also responsive to the needs of diverse populations. UNM is dedicated to translating research findings into practical applications, ultimately contributing to the enhancement of medical knowledge and the quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Albuquerque, New Mexico, United States
Patients applied
Trial Officials
Katie Witkiewitz, PhD
Principal Investigator
University of New Mexico
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials